Pembrolizumab-induced demyelinating polyradiculoneuropathy

New England Journal of Medicine

Volumn 375, Issue 3, 2016, Pages 296-297

  De Maleissye, Marie Florence ^a   Nicolas, Guillaume ^a   Saiag, Philippe ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; IMMUNOGLOBULIN; IPILIMUMAB; PEMBROLIZUMAB; PREDNISOLONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; AREFLEXIA; CASE REPORT; DEMYELINATING POLYRADICULONEUROPATHY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; GENE MUTATION; HUMAN; HYPESTHESIA; INOPERABLE CANCER; LETTER; LIMB WEAKNESS; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; NERVE CONDUCTION; ONCOGENE N RAS; PARESTHESIA; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; VERY ELDERLY; ACTION POTENTIAL; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

ACTION POTENTIALS; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; MUSCLE, SKELETAL; POLYRADICULONEUROPATHY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84979650135     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1515584     Document Type: Letter

References (5)

1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40.
2. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin 2013;31:491-510.
3. Anthoney DA, Bone I, Evans TRJ. Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann Oncol 2000;11:1197-200.
4. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011;22:991-3.
5. Johnson DB, Wallender EK, Cohen DN, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 2013;1:373-7.